Hepatorenal syndrome

Seminars in Liver Disease

Volumn 17, Issue 3, 1997, Pages 233-247

  Bataller, Ramón ^a   Ginès, Pere ^a   Guevara, Mónica ^a   Arroyo, Vicente ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Ascites; Cirrhosis; Vasoactive systems

Indexed keywords

ASCITES; DIALYSIS; HEPATORENAL SYNDROME; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; PERITONEUM VEIN SHUNT; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; VASOCONSTRICTION;

EID: 0030886154     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007201     Document Type: Review

References (159)

1. Papper S. Hepatorenal syndrome. In: Epstein M (ed): The kidney in liver disease, 1st ed. New York, Elsevier Biomedical, 1978, pp 91-112.
2. LaVilla G, Ginès P, Arroyo V: Hepatorenal syndrome and ascites. In: Bayless TM (ed): Current therapy in gastroenterology and liver disease, 3rd ed. Toronto, BC Decker, 1990, pp 425-9.
3. Levy M. Hepatorenal syndrome: Kidney Int 43:737-53, 1993.
4. DiBona GF. Nephrology Forum: Renal nerve activity in hepatorenal syndrome. Kidney Int 25:841-53, 1984.
5. Epstein M. Hepatorenal syndrome. In: Epstein M (ed): The kidney in liver disease, 4th ed. Philadelphia, Hanley & Belfus, 1996, pp 75-108.
6. Flint A: Clinical report on hydro-peritoneum, based on an analysis of forty-six cases. Am J Med Sci 45:306-39, 1863.
7. Frerichs T: Tratado Práctico de las Enfermedades del Hígado, de los Vasos Hepáticos y de las Vias Biliares. Madrid, Librería Extranjera y Nacional, Científica y Literaria. 1877, pp 362-3.
8. Hecker R, Sherlock S: Electrolyte and circulatory changes in terminal liver failure. Lancet 2:1121-5, 1956
9. Papper S, Belsky JL, Bleifer KH: Renal failure in Laennec's cirrhosis of the liver: I. Description of clinical and laboratory features. Ann Intern Med 51:759, 1959
10. Koppel MH, Coburn JN, Mims MM, et al: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 289:1155-9, 1969.
11. Iwatsuki S, Popovtzer MM, Corman JL, et al: Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med 280:1367-71, 1969.
12. Schroeder ET, Shear L, Sancetta SM, Gabunza JG Renal failure in patients with cirrhosis of the liver. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med 43:887-96, 1967.
13. Epstein M, Berck DP, Hollemberg NK, et al: Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49:175-85, 1970.
14. Fine LG, Sakhrani LM. Toward a physiological definition of the hepatorenal syndrome. In: Epstein M (ed): The kidney in liver disease, 2nd ed. New York, Elsevier Biomedical, 1983, pp 107-16.
15. Bartoli E, Chiandussi L: Hepato-renal syndrome. Padova, Piccin Medical Books, 1979.
16. Arroyo V, Ginès P, Gerbes AL, et al: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23,1:164-73, 1996.
17. Wilkinson S, Arroyo V, Gazzard BG, et al: Relation of renal impairment and haemorragic diathesis to endotoxaemia in fulminant hepatic failure. Lancet 1:521-4, 1974.
18. Lancestremere RG, Davidson PL, Earley Le, et al: Renal failure in Laennec's cirrhosis. II. Simultaneous determination of cardiac output and renal hemodynamics. J Clin Invest 41:1922-7, 1962
19. Kew MC, Brunt PW, Varma RR, et al: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 2:504-10, 1971.
20. Sacerdoti D, Bolognesi M, Merkel C, et al: Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 17:219-24, 1993.
21. Platt JF, Marn CS, Bahga PK, et al: Renal dysfunction in hepatic disease: early identification with renal duplex Doppler US in patients who undergo liver transplantation. Radiology 183:801-6, 1992.
22. Maroto A, Ginès A, Saló J, et al: Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index. Hepatology 20:839-44, 1994.
23. Ginès A, Escorsell A, Ginès P, et al: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105:229-36, 1993.
24. Platt JF, Ellis JH, Rubin JM, et al: Renal duplex doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 20:362-9, 1994.
25. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 46:1894-1906, 1967.
26. Epstein M, Scheneider N, Belefer B: Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 89:1175-87, 1979.
27. Fernández-Seara J, Prieto J, Quiroga J, et al: Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97:1304-12, 1989.
28. Maroto A, Ginès P, Arroyo V, et al: Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 17:788-93, 1993.
29. Arroyo V, Ginès P, Rimola A, et al: Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 81:104-22, 1986
30. Arroyo V, Ginès P, Jiménez W, et al: Ascites, renal failure and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis and treatment. In McIntyre N, Benhamou JP, Bircher J, et al (eds): Oxford texbook of clinical hepatology. Oxford, Oxford Medical Publications, 1991, pp 429-70.
31. Brezis M, Rosen S, Franklin HE: Acute renal failure. In: Brenner BM, Rector FC (eds): The kidney. Philadelphia, WB Saunders, 1991, pp 993-1061.
32. Hall JE, Brands MW: The renin-angiotensin systems: renal mechanisms and circulatory homeostasis. In: Seldin DW, Giebsch G (eds): The kidney: Physiology and pathophysiology. New York, Raven Press, 1992, pp 1455-1504.
33. Knox FG, Granger JP: Control of sodium excretion: an integrative approach. In Windhager EE (ed): Handboook of physiology. Renal physiology (Section 8), 1st ed. New York, Oxford University Press, 1992, pp 927-67.
34. Moss NG, Colindres RE, Gottschalk CW: Neural control of renal function. In: Windhager EE (ed): Handboook of physiology. Renal physiology (Section 8), 1st ed. New York, Oxford University Press, 1992, pp 1061-1128.
35. Barnardo DE, Summerskill WH, Strong CG, et al: Renal function, renin activity and endogenous vasoactive substances in cirrhosis. Am J Dig Dis 15:419-25, 1970.
36. Schroeder ET, Eich RH, Smulyan H, et al: Plasma renin level in hepatic cirrhosis. Relation to functional renal failure. Am J Med 49:186-91, 1970.
37. Wong PY, Talamo RC, Williams GH: Kallikrein-kinin and renin-angiotensin systems in functional renal failure of cirrhosis of the liver. Gastroenterology 73:1114-8, 1977.
38. Arroyo V, Planas R, Gaya J, et al: Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 13:271-8, 1983.
39. Henriksen H, Ring-Larsen H, Christensen NJ: Sympathetic nervous activity in cirrhosis. A survey of plasma catecholamine studies. J Hepatol 1:55-65, 1984.
40. Ring-Larsen H, Henriksen JH, Christensen NJ: Increased sympathetic activity in cirrhosis. N Engl J Med 308:1209-10, 1983.
41. Zambraski EJ, DiBona G. Renal sympathetic nervous system in hepatic cirrhosis. In: Epstein M (ed): The kidney in liver disease, 4th ed. Philadelphia, Hanley & Belfus 1996, pp 405-22.
42. Schroeder ET, Anderson GH, Goldman SH, et al: Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 9:511-19, 1976.
43. Arroyo V, Bosch J, Mauri M, et al: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11:221-9, 1981.
44. Pariente EA, Bataille C, Bercoff E, et al: Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88:1255-9, 1985.
45. Lobden I, Shore A, Wilkinson R, et al: Captopril in the hepatorenal syndrome. J Clin Gastroenterol 7:354-60, 1985.
46. Clària J, Jiménez W, Arroyo V, et al: Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 100:494-8, 1991.
47. Gavras I, Gavras H. Role of vasopressin in hypertensive disorders. In: Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, diagnosis and management, 2nd ed. New York, Raven Press, 1995, pp 789-800.
48. Pérez-Ayuso RM, Arroyo V, Camps J, et al: Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 26:72-80, 1986.
49. Uchihara M, Izumi N, Sato C, et al: Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 16:95-102, 1992.
50. Uemasu J, Matsumoto H, Kawasaki H: Increased plasma endothelin levels in patients with liver cirrhosis. Nephron 60: 380-86, 1992.
51. Moore K, Wendon J, Frazer M, et al: Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774-8, 1992.
52. Asbert M, Ginès A, Ginès P, et al: Circulating levels of endothelin in cirrhosis. Gastroenterology 104:1485-91, 1993
53. Moller S, Emmeluth C, Henriksen JH: Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 19:285-90, 1993.
54. Saló J, Francitorra A, Folio A, et al: Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. J Hepatol 22:389-98, 1995.
55. Soper PR, Latif AB, Bending MR: Amelioration of hepatorenal syndrome with selective endothelin-A anatagonist. Lancet 347:1842-3, 1996.
56. Moller S, Gülberg V, Henriksen JH, Gerbes AL: Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic hemodynamics. J Hepatol 23:135-44, 1995.
57. Leivas A, Jiménez W, Lamas S, et al: Endothelin-1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology 108:1842-8, 1995.
58. Sanyal AJ, Gehr T, Freedman AM, et al: Increased splanchnic endothelin-1 plays a role in the pathogenesis of ascites (abstract). Hepatology 20:113A, 1994.
59. González-Campoy JM, Knox FG. Integrated responses of the kidney to alterations in extracellular fluid volume. In: Seldin DW, Giebsch G (eds): The kidney: Physiology and pathophysiology, 2nded. New York, Raven Press, 1992, pp 2041-8.
60. Llach J, Ginès P, Arroyo V, et al: Effect of dipyridamole on kidney function in cirrhosis. Hepatology 17:59-66, 1993.
61. Huber M, Kastner S, Scholmerich J, et al: Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest 19:53-60, 1989.
62. Moore K, Taylos GW, Maltby NH, et al: Increased production of cysteinyl leukotrienes in hepatorenal syndrome. J Hepatol 11:263-71, 1990.
63. Bourgoignie JJ, Valle GA Endotoxin and renal failure in liver disease. In: Epstein M (ed): The kidney in liver disease, 3rd ed. Baltimore, Williams & Wilkins, 1988, pp 486-507.
64. Folio A, LLovet JM, Navasa M, et al: Renal impairment following spontaneous bacterial peritonitis in cirrhosis. Incidence, clinical course, predictive factors and prognosis. Hepatology 20:1495-1501, 1994.
65. Clemente C, Bosch J, Rodés J, et al: Functional renal failure and haemorragic gastritis associated with endotoxaemia in cirrhosis. Gut 18:556-60, 1977.
66. Gatta A, Milani L, Merckel C, et al: Lack of correlation between endotoxemia and renal hypoperfusion in cirrhotics without overt renal failure. Eur J Clin Invest 12:417-22, 1982.
67. Coratelli P, Passavanti G, Munno I, et al: New trends in hepatorenal syndrome. Kidney Int 28:S143-7, 1985.
68. Conrad KP, Dunn MJ: Renal prostaglandins and other eicosanoids In: Windhager EE (ed): Handboook of physiology. Renal physiology (Section 8), 1st ed. New York, Oxford University Press, 1992, pp 1707-58.
69. Boyer TD, Zia P, Reynolds TB: Effects of indomethacin and prostaglandin A1 in renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77:215-22, 1979.
70. Mirouze D, Zipser RD, Reynolds TB: Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 3:50-55, 1983.
71. Planas R, Arroyo V, Rimola A, et al: Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 84:247-52, 1983.
72. Quintero E, Ginès P, Arroyo V, et al: Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 42:298-303, 1986.
73. Romero JC, Lahera V, Salom MG, et al. Role of endothelium-dependent relaxing factor nitric oxide on renal function. J Am Soc Nephrol 2:1371-7, 1992
74. Garcia-Estañ J, Atucha N, Mario J, et al: Increased endothelium-dependent renal vasodilation in cirrhotic rats. Am J Physiol 267:R549-53, 1994.
75. Clària J, Jiménez W, Ros J, et al: Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 15:343-9, 1992.
76. Ros J, Jiménez W, Bosch-Marcé M, et al: Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 21:915-20, 1995.
77. Levicki JA, Protter AA Physiological studies of the natriuretic peptide family. In: Laragh JH, Brenner BH (eds): Hypertension: Pathphysiology, diagnosis and management. New York, Raven Press, 1995, pp 1029-53.
78. Angeli P, Jiménez W, Arroyo V, et al: Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 20:948-54, 1994.
79. Alvestrand A, Bergstrom J: Glomerular hyperfiltration after protein ingestion, during glucagon infusion, and in insulin-dependent diabetes is induced by a liver hormone: deficient production of this hormone in hepatic failure causes hepatorenal syndrome. Lancet 1:195-7, 1984.
80. Lang F, Tschernko E, Schulze E, et al: Hepatorenal reflex regulating kidney function. Hepatology 14:590-98, 1991.
81. Safirstein R, Levitt MF. A hepatorenal depressor reflex: a possible clue to the pathogenesis of the hepatorenal syndrome. Hepatology 14:734-5, 1991.
82. Lang F, Gerok W, Haussinger D: New clues to the pathophysiology of hepatorenal failure. Clin Investig (Germany) 71:93-7, 1993.
83. Kostreva DR, Castaner A, Kampine JP: Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nervous activity. Am J Physiol 238:R390-4, 1980.
84. Levy M, Wexler MJ: Sodium excretion in dogs with low grade caval constriction: role of hepatic nerves. Am J Physiol 253:F672-8, 1987.
85. Levy M, Wexler MJ Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 253:F664-78, 1987
86. Unikowsky B, Wexler MJ, Levy M: Dogs with experimental cirrhosis of the liver but without intrahepatic hypertension do not retain sodium or form ascites. J Clin Invest 72:1594-1604, 1983.
87. Schrier RW, Arroyo V, Bernardi M, et al: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Hepatology 8:1151-7, 1988.
88. Guevara M, Ginès P, Fernández-Esparrach G, et al: Effects of normalization of vasoconstrictor systems on renal function in cirrhotic patients with hepatorenal syndrome (HRS) (abstract). J Hepatol 25(suppl 1):71, 1996.
89. Salmerón JM, Ruiz del Arbol L, Ginès A, et al: Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 17:800-806, 1993.
90. Albillos A, LLedó JL, Rossi I, et al: Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and liver and renal function. Gastroenterology 109: 1257-65, 1995.
91. Rodès J, Bosch J, Arroyo V: Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Mcd J 55:492-7, 1975.
92. Reynolds TB, Lieberman FL, Redecker AA. Functional renal failure with cirrhosis: The effect of plasma expansion therapy. Medicine (Baltimore) 46:191-6, 1967.
93. Rodés J, Bosch J, Terés J: La insuficiencia renal funcional terminal de la cirrosis hepática con ascitis. Rev Clin Esp 31:475-82, 1970.
94. Shear L, Klemerman J, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver: I. Clinical and pathologic characteristics. Am J Med 39:184-92, 1965
95. Baldus WP, Summerskill WH: Liver-kidney interrelationships. In: Schiff L (ed): Diseases of the liver, 4th ed. Philadelphia, JB Lippncott, 1975, pp 445-65.
96. Baldus WP, Feichter RN, Summerskill WHJ, et al: The kidney in cirrhosis I. Clinical and biochemical features of azotemia in hepatic failure. Ann Intern Med 60:353-60, 1964
97. Vesin P: Late functional renal failure in cirrhosis with ascites: Pathophysiology, diagnosis and treatment. In: Martinin GA, Sherlock S (eds): Aktuelle Probleme der Hepatologie. Stuttgart, Georg Thieme Verlag, 1962, pp 98-108.
98. Ginès P, Titó LI, Arroyo V, et al: Randomized commparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94:1493-1502, 1988.
99. Ginès P, Saló J: Paracentesis in the management of cirrhotic ascites In: Holstege A, Hahn EG, Schölmerich J (eds): Portal hypertension. Dordrecht, Kluwer, 1995, pp 377-84.
100. Linas SL, Schaffer JW, Moore EE, et al: Peritoneovenous shunt in the management of the hepatorenal syndrome. Kincy Int 30:736-40, 1986.
101. Kleinknecht D: Management of acute renal failure. In: Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E (eds): Oxford Textbook of Clinical Nephrology, 1st ed Oxford, Oxford University Press, 1015-25, 1992.
102. Arroyo V, Rodés J: A rational approach to the treatment of ascites. Postgrad Med J 51:558-62, 1975.
103. Papadakis MA, Arieff AI: Unpredictability of clinical evaluation of renal function in cirrhosis: a prospective study. Am J Med 82:945-52, 1987.
104. Caregaro L, Menon F, Angeli P, et al: Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154:201-5, 1994.
105. Schuster VL, Seldin DW: Renal clearance. In: Seldin DW, Giebsch G (eds): The kidney: Physiology and pathophysiology. New York, Raven Press, 1992, pp 943-78.
106. Levey AS. Laboratory assessment of renal disease: Clearance, urinalysis, and renal biopsy. In: Laragh JH, Brenner BH (eds): Hypertension: Pathphysiology, diagnosis and management. New York, Raven Press, 1995, pp 919-68.
107. Earley LE. Conclusive remarks and presentation of diagnostic criteria of the hepatorenal syndrome. In: Bartoli E, Chiandussi L (eds): Hepato-renal syndrome Padova, Piccin, pp 493-506, 1979.
108. Cabrera J, Arrroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta-2 microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 82:97-105, 1982.
109. Dudley FJ, Kanel GC, Wood LJ, et al: Hepatorenal syndrome without sodium retention Hepatology 6:248-59, 1986.
110. Mandai AK, Lansing M, Fahmy A. Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study. Am J Kidney Dis 34:2363-74, 1982.
111. Hall PW, Ricanati EJ: Renal handling of beta-2-microglobulin in renal disorders; with special reference to hepatorenal syndrome. Nephron 27:62-5, 1981.
112. Gatta A, Amodio P, Frigo A, et al: Evaluation of renal tubular damage in liver cirrhosis by urinary enzymes and beta-2-microglobulin excretions. Eur J Clin Invest 11:239-43, 1981.
113. Solís-Herruzo JA, Garcia-Cabezudo J, Diaz-Rubio C, et al: Urinary excretion of enzymes in cirrhotics with renal failure. J Hepatol 3:123-30, 1986.
114. Fevery J, Van Cutsem E, Nevens F, et al: Reversal of hepatorenal syndrome in four patients by peroral mysoprostol (prostaglandin E1 analogue) and albumin administration J Hepatol 11:153-8, 1990
115. Ginès A, Salmerón JM, Ginès P, et al: Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure J Hepatol 17:220-6, 1993.
116. Arieff AI, Chidsey CA. Renal function in cirrhosis and the effects of prostaglandin A1. Am J Med 56:695-703, 1974.
117. Zussman RM, Axelrod L, Tolkoff-Rubin N. The treatment of the Hepatorenal Syndrome with intrarenal administration of prostaglandin E1. Prostaglandins 13:819-30, 1977.
118. Barnardo DE, Baldus WP, Maher FT: Effects of dopamine on renal function in patients with cirrhosis. Gastroenterology 58:524-31, 1970.
119. Bennet WM, Keefe E, Melnyk C, et al: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 135:964-71.
120. Laragh JH, Cannon PJ, Bentzel CJ, et al: Angiotensin II, norepinephrine and renal transport of electrolytes and water in normal man and in cirrhosis with ascites. J Clin Invest 42:1179-92, 1963.
121. Gornel DL, Lancestremere RG, Papper S, et al: Acute changes in renal excretion of sodium and solute in patients with Laennec's cirrhosis, induced by the administration of the pressor amine, metaraminol. J Clin Invest 41:594-603, 1963.
122. Lancestremere RG, Klinger EL, Frisch E, et al: Simultaneous determination of cardiac output and renal function in patients with Laennec's cirrhosis during the administration of the pressor amine metaraminol. J Lab Clin Med 61:820-5, 1963.
123. Lenz K, Hörnatgl H, Druml W, et al: Beneficial effect of 8-or-nithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 30:90-6, 1989.
124. Lenz K, Hörnatgl H, Druml W, el al: Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis Gastroenterology 101:1060-1067, 1991.
125. Saló J, Ginès A, Quer JC, et al: Renal and neurohumoral changes following simultaneous administration of systemic vasoconstrictors and renal vasodilators in cirrhotic patients with hepatorenal syndrome. J Hepatol (in press).
126. Epstein M. Peritovenous shunt in the management of ascites and the hepatorenal syndrome. In. Epstein M (ed): The kidney in liver disease, 4th ed. Philadelphia, Hanley & Belfus, 1996, pp 491-507.
127. Blendis LM, Greig PD, Langer B, et al: Renal and hemodynamic effect of the peritoneovenous shunt for intractable hepatic ascites Gastroenterology 77:250-57, 1979.
128. Fullen WD: Hepatorenal syndrome: Reversal by peritoneovenous shunt. Surgery 82:337-41, 1977.
129. Schwartz ML, Vogel SB: Treatment of hepatorenal syndrome. Am J Surg 139:370-3, 1980.
130. Pladson TR, Parrish RM: Hepatorenal syndrome: Recovery after peritoneous shunt. Arch Intern Med 137:1248-9, 1977.
131. Daskalopoulos G, Jordan DR, Reynolds TB: Randomized trial of peritoneovenous shunt (PVS) in the treatment of hepatorenal syndrome (HRS) [abstract]. Gastroenterology 88:88, 1995.
132. Schroeder ET, Numann PJ, Chamberllain BE: Functional renal failure in cirrhosis. Recovery after portacaval shunt. Ann Intern Med 72:293-8, 1970.
133. Ariyan S, Sweeney T, Kerstein MD. The hepatorenal syndrome: recovery after portacaval shunt. Ann Surg 181: 847-9, 1975.
134. Wapnick S, Grosberg S, Kinney M, LeVeen HH: LeVeen continuous peritoneal-jugular shunt: improvement of renal function in ascitic patients. JAMA 237:131-3, 1977.
135. Palmaz JC, Garcia F, Sibbit RR, et al: Expandable intrahepatic portocaval shunt stents in dogs with chronic portal hypertension. AJR 147:1251-4, 1986.
136. Richter GM, Noeldge G, Palmaz JC, et al: Transjugular intrahepatic portocaval stent shunt. preliminary clinical results. Radiology 174:1027-30, 1990.
137. Ring EJ, Lake JR, Roberts JP, et al: Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med 116:304-9, 1992.
138. Rössle M, Haag K, Ochs A, et al: The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 330:165-71, 1994.
139. Sanyal AJ, Freedman AM, Shifman ML, et al: Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 20:46-65, 1994.
140. Freedman AM, Sanyal AJ. Complications of transjugular portosystemic shunts. Semin Intervent Radiol 11:161-77, 1994.
141. Somherg KA: Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites and hepatorenal syndrome. In Epstein M (ed): The kidney in liver disease, 4th ed. Philadelphia, Hanley & Belfus, 1996, pp 507-16.
142. Somberg KA, Lake JR, Tomlanovich SJ, et al: Transjugular intrahepatic portosystemic shunt for refractory ascites: Assesment of clinical and humoral response and renal function. Hepatology 21:709-16, 1995.
143. Quiroga J, Sangro B, Nun̄ez M, et al: Transjugular intrahepatic portal-systemic shunt in the management of refractory ascites: Effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 21:986-94, 1995.
144. Ochs A, Rössle M, Haag K, et al: The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332:1192-7, 1995.
145. Brensing KA, Textor J, Raab P, et al: Sustained improvement of hepatorenal syndrome after TIPS-insertion in patients with terminal liver cirrhosis not eligible for transplantation [abstract]. Gastroenetrology 110:A1158, 1996.
146. Alam I, Bass NM, LaBerge JM, et al: Treatment of hepatorenal syndrome with the transjugular intrahepatic portosystemic shunt (TIPS) [abstract] Gastroenterology 108:1024A, 1995.
147. Pérez GO, Golper TA, Epstein M, et al: Dialysis, hemofiltration, and other extracorporeal techniques in the treatment of renal complications of liver disease. In: Epstein M (ed): The kidney in liver disease, 4th ed. Philadelphia, Hanley & Belfus, 1996, pp 517-28.
148. Keller F, Wagner K, Lenz T, et al: Hemodialysis in hepatorenal syndrome: report of two cases. Gut 26:208-11, 1986.
149. Kearns PJ, Polhemus RJ, Oakes D, Rabkin R: Hepatorenal syndrome managed with hemodialysis then reversed by peritoneovenous shunting. J Clin Gastroenterol 7:341-3, 1985.
150. Topchiashvili ZA, Sergienko VS: Hemodialysis in hepatorenal insufficiency. Khirurgiia 47:14-6, 1971.
151. Klingler EL Jr, Cronin RJ: Renal failure in cirrhosis of the liver: Observations during intermittent hemodialysis. Abstracts Am Soc Artif Intern Organs 18:26, 1972.
152. Ellis D, Avner ED: Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation. Clin Nephrol 25:295-303, 1986.
153. Strand V, Mayor G, Ristow G, et al: Concomitant renal and hepatic failure treated by polyacrylonitrile membrane hemodialysis. Int J Artif Organs 4:136-9, 1981.
154. Gonwa TA, Wilkinson AH. Liver transplantation and renal function: Results in patients with and without hepatorenal syndrome. In: Epstein M (ed): The kidney in liver disease, 4th ed. Philadelphia, Hanley & Belfus, pp 529-42.
155. Gonwa TA, Morris CA, Goldstein RM, et al: Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991:428-30, 1991.
156. Gonwa TA, Klintmalm GB, Jennings LS, et al: Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59:361-5, 1995
157. Seu P, Wilkinson AH, Shaked A, Busuttil BW: The hepatorenal syndrome in liver transplant recipients. Am Surg 57:806-9, 1991.
158. Rimola A, Gavaler JS, Schade RR, et al: Effects of renal impairment on liver transplantation. Gastroenterology 93:148-56, 1987.
159. Baliga P, Merion RM, Turcottle JG, el al. Preoperative risk factor assessment in liver transplantation Surgery 112:704-10, 1992.